Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Myriad Genetics Inc
(NQ:
MYGN
)
18.49
-0.01 (-0.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Myriad Genetics Inc
< Previous
1
2
3
Next >
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
April 17, 2024
80% of people diagnosed with anxiety, depression report losing years or decades of time
From
Myriad Genetics, Inc.
Via
GlobeNewswire
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
April 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
April 09, 2024
Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
March 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
March 20, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the
February 27, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
February 27, 2024
Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 21, 2024
Management will also participate in two upcoming healthcare conferences
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
February 15, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
February 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
January 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
January 18, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
January 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
December 21, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
December 20, 2023
The Myriad Collaborative Research Registry has more than one million patient cases
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
November 20, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
November 16, 2023
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx...
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Participate in Stephens Annual Investment Conference
November 09, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
November 08, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
November 08, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
November 06, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
November 01, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
October 31, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
October 26, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
October 20, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
September 28, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
September 19, 2023
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
September 19, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
September 18, 2023
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing
From
Myriad Genetics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.